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This study investigated the protective effects of melatonin and folic acid against carbon tetrachloride (CCl4)-
induced hepatic injury in rats. Oxidative stress, liver function, liver histopathology and serum lipid levels were
evaluated. The levels of protein kinase B (Akt1), interferon gamma (IFN-γ), programmed cell death-receptor (Fas)
and Tumor necrosis factor-alpha (TNF-α) mRNA expression were analyzed. CCl4 significantly elevated the levels of
lipid peroxidation (MDA), cholesterol, LDL, triglycerides, bilirubin and urea. In addition, CCl4 was found to
significantly suppress the activity of both catalase and glutathione (GSH) and decrease the levels of serum total
protein and HDL-cholesterol. All of these parameters were restored to their normal levels by treatment with
melatonin, folic acid or their combination. An improvement of the general hepatic architecture was observed in
rats that were treated with the combination of melatonin and folic acid along with CCl4. Furthermore, the
CCl4-induced upregulation of TNF-α and Fas mRNA expression was significantly restored by the three treatments.
Melatonin, folic acid or their combination also restored the baseline levels of IFN-γ and Akt1 mRNA expression. The
combination of melatonin and folic acid exhibited ability to reduce the markers of liver injury induced by CCl4 and
restore the oxidative stability, the level of inflammatory cytokines, the lipid profile and the cell survival Akt1 signals.
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Carbon tetrachloride (CCl4) is a well-known compound
for the production of chemical hepatic injury [1] mediated
by metabolites that react with antioxidant enzymes, such
as glutathione (GSH), catalase and superoxide dismutase,
[2] and increase the level of inflammatory cytokines. Anti-
oxidants exhibit a strong protection against CCl4-induced
hepatic toxicity [3,4]. Previous studies have shown that
melatonin and folic acid are very potent antioxidants that
scavenge reactive oxygen species (ROS) [5]. The release of
melatonin, a pineal gland hormone [6], is mainly impli-
cated in the regulation of the sleep/wake cycle and the hor-
monal regulation of sexual development [7]. Melatonin has
been found to be more effective in the protection against
oxidative damage than other antioxidants, including* Correspondence: hossamebaid@yahoo.com
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reproduction in any medium, provided the orvitamin E, glutathione and mannitol [8]. However, the cir-
culating levels of melatonin following oral administration
can increase both the mRNA levels and the activities of
antioxidant enzymes [9]. The administration of melatonin
to aged mice was able to inhibit increase the relative ex-
pression of pancreatic genes that are involved in inflamma-
tion, oxidative stress and apoptosis [10] and decrease the
mRNA expression of Tumor necrosis factor-alpha (TNF-
α), interleukin-1 β (IL-1β), nuclear factor (NF)-κB and
transcriptional repressor (NKAP) [11]. Melatonin also
reduces cytokine levels in surgical neonates [12]. Melatonin
prevents hemorrhagic shock-induced liver injury in rats
through an Akt-dependent HO-1 pathway [13].
Epidemiological studies have shown that folic acid
supplementation can reduce the risk of cardiovascular
and hematological diseases [14], neurological and neuro-
psychiatric disorders [15], neural tube defects [16] and
several types of cancer, including cervical, lung, brain,
pancreatic, colorectal and breast cancer [17]. The anti-
oxidant activity of folic acid is thought to be involved intd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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acid has been reported to have an antioxidant effect
against ROS and an alleviating role in hyperhomocystei-
nemia and its associated endothelial dysfunction [19].
Moreover, the anti-inflammatory effect of folic acid is
manifested by a decrease in the levels of interleukin and
C-reactive proteins [20].
The combination of melatonin and folic acid improves
oocyte quality and thus the pregnancy outcome in
women with a history of low oocyte quality [21]. In par-
ticular, because melatonin and folic acid are very potent
antioxidants in the scavenging of ROS, their effects on
CCl4-induced hepatic toxicity were investigated in this
study. However, no reports are currently available on the
protective effect of folic acid alone or in combination
with melatonin against the oxidative stress that occurs
from CCl4- induced hepatic injury, which is the subject
of this study. Folates function as cofactors in the transfer
and utilization of carbon groups and therefore play a key
role in the biosynthesis of purines and pyrimidines and
the regeneration of methionine. The re-methylation of
homocysteine to form methionine requires folate, which
alters the secretion of melatonin in rats [22]. Therefore,
we hypothesized that the combination of folic acid and
melatonin would prove useful in the prevention of vari-
ous liver injuries induced by oxidative stress.
Materials and methods
Animals and experimental design
A total of 56 male Wistar rats (Rattus norvegicus) weigh-
ing 150–170 g (20 ± 1 weeks) was obtained from the
College of Pharmacy, King Saud University. Throughout
the experiment, the animals were housed in polypropyl-
ene cages, one for each group of eight animals. They
were allowed to acclimatize to the laboratory environ-
ment for seven days before the beginning of the experi-
ment. The animals were maintained at 18-22°C, kept on
a 12:12 h light:dark cycle and provided with food and
water ad libitum. All animal procedures were conducted
in accordance with the standards set forth in the guide-
lines for the care and use of experimental animals by the
Committee for the Purpose of Control and Supervision
of Experiments on Animals and the National Institutes
of Health. The study protocol was approved by the Ani-
mal Ethics Committee of the Zoology Department in the
College of Science at King Saud University.
The rats were divided into seven groups, each of which
contained eight rats. Group 1 served as the control and
only received the vehicle. Group 2 received a single dose
of 1 ml/kg CCl4 in liquid paraffin (1:1 volume) through
an intraperitoneal (IP) injection [23] (inoculated dose
was 0.1 ml). Groups 3 and 4 were pretreated with a daily
dose of 2.5 mg/kg folic acid and 10 mg/kg melatonin S.
C, respectively [24], for 3 weeks before receiving theCCl4 challenge. Group 5 received the same doses of folic
acid as group 3; similarly, Group 6 was treated with the
same melatonin treatment protocol as group 4. Group 7
was pre-treated with a combination of folic acid and
melatonin for 3 weeks before CCl4 challenge. The sam-
ples were collected 2 days after the injection of CCl4.
Chemicals
The chemicals 5,5-dithiobis-2-nitrobenzoic acid (DTNB),
dihydrogen phosphate, trichloroacetic acid, carbon tetra-
chloride, and thiobarbituric acid were purchased from
Merk Company, Darmstadt, Germany. Melatonin was
obtained from MPBiomedicals, LLC, Llkirch, France. Folic
acid was purchased from Sigma Chemical Company,
Louis, MO, USA.
Blood and liver samples
Two days after treatment, the animals from all groups
were autopsied under light ether anesthesia. The blood
was drawn from the animals by puncturing the retro-
orbital venous sinus with capillary tubes until killing.
The blood was collected in heparin-coated centrifuge
tubes, centrifuged at 200 × g for 10 minutes, then plasma
was separated in Eppendorf tubes and stored at −30°C.
Whole blood was used for the determination of the level
of hydroperoxide, whereas separated plasma was used to
determine the level of liver enzymes, the amount of total
protein and the lipid profile.
The liver was removed, washes with saline and cut
into two parts, one part was used for the histological
study and the other part was used for the assessment of
lipid peroxidation (MDA), GSH and catalase. The hep-
atic tissues were homogenized (Automated homogenizer,
IKA, T25D, Germany) in 10 mM KCl in 1.15% phos-
phate buffer and ethylenediamine tetraacetic acid
(EDTA; pH 7.4) and centrifuged at 5000 × g for 10 min.
The supernatant was used to assay the level of thiobarbi-
turic acid reactive substances (TBARS) and to estimate
the amount of GSH and catalase.
Biochemical analysis
Estimation of lipid peroxides
The blood hydroperoxide level was evaluated using the
free radical analytical system (Iran, Parma, Italy), which
is a colorimetric test that takes advantage of the ability
of hydroperoxides to generate free radicals after reacting
with some transitional metals. In this test, a colored
complex appears when buffered chromogenic substances
are added to a solution that contains hydroperixodes.
The amount of complex that was formed can then be
measured by a spectrophotometer. The lipid peroxida-
tion level, or the amount of TBARS in the liver, was
measured by a method described by Ohkawa, et al. [25].
The liver tissue was homogenized in ice-cold 0.15 M
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Using 1,1,3,3-tetramethoxypropane as the standard, the
absorbance was used to determine the concentration of
TBARS, which was expressed as nm of MDA per mg










R: GGGGGCTGGCTCTGTGAGGAAssay of hepatic reduced glutathione
The reduced form of glutathione was determined using
DTNB as the coloring reagent and following the method
described by Moron et al. [26]. The absorbance was read
at 412 nm using a spectrophotometer and the GSH con-
centration was calculated from a standard curve.
Determination of hepatic catalase
The level of catalase activity was estimated in the liver
homogenate by the method described by Aebi [27]. The
specific activity of catalase is expressed in units of moles
of H2O2 consumed/min/mg of protein. The difference
in the absorbance at 240 nm per unit time was used to
determine the catalase activity.
Liver function tests and lipid profile
The levels of AST, ALT, ALP, bilirubin, LDH, cholesterol,
triglycerides, LDL, HDL, protein, and urea were mea-
sured in the plasma samples obtained from all the
groups. The measurements were performed in accord-
ance with the manufacturer protocols of the Bio Merieux
kits, France. The amounts of AST, ALT and ALP were
determined kinetically, whereas the other proteins were
evaluated by colorimetry. The intensity of coloration was
measured using the UV/Visible-Model-80-2106-00 spectro-
photometer, Pharmacia Biotech, Cambridge, England.
Histological study
The liver sample from each animal was processed using
light microscopy. The tissue sections were fixed in 10%
neutral buffered formalin and embedded in paraffin. The
paraffin sections were then stained with hematoxylin-
eosin (H&E). Mallory Trichrome was used for detecting
the collagen deposition in the hepatic tissue. The degree
of liver damage was examined blindly using a Leica
DMRB/E light microscope (Heerbrugg, Switzerland).
RNA extraction and cDNA synthesis
The total RNA from the liver tissue homogenates was
isolated using TRIzol reagent (InvitrogenW). The isola-
tion was performed according to the manufacturer’s
instructions and quantified by measuring the absorbance
at 260 nm. The cDNA synthesis was performed using
the High-Capacity cDNA reverse transcription kit (Ap-
plied BiosystemsW) according to the manufacturer’s
instructions. A total of 1.5 μg of total RNA from each
sample was added to a mixture of 2.0 μl of 10x reversetranscriptase buffer, 0.8 μl of 25x dNTP mix (100 mM),
2.0 μl of 10x reverse transcriptase random primers,
1.0 μl of MultiScribe reverse transcriptase, and 3.2 μl of
nuclease-free water. The final reaction mixture was kept
at 25°C for 10 min, heated to 37°C for 120 min, heated
to 85°C for 5 s, and then cooled to 4°C.
Quantification of mRNA expression by real-time
polymerase chain reaction
The quantitative analysis of the level of mRNA expression
of the target genes was achieved by RT-PCR. The cDNA
from the above preparation was subjected to PCR amplifi-
cation using 96-well optical reaction plates in the ABI
Prism 7500 System (Applied BiosystemsW). The 25-μl
reaction mixture in each well contained 0.1 μl of 10 μM
forward primer and 0.1 μl of 10 μM reverse primer for a
final concentration of 40 μM of each primer, 12.5 μl of
SYBR Green Universal Mastermix (Applied BiosystemsW),
11.05 μl of nuclease-free water, and 1.25 μl of the cDNA
sample. The primers used in the current study were
chosen from the PubMed database (pubmed.com)
(Table 1). The RT-PCR data were analyzed using the rela-
tive gene expression method, as described by the Applied
BiosystemsW User Bulletin No. 2. The data are therefore
presented as the fold change in gene expression normal-
ized to the endogenous reference gene and relative to a
calibration gene.
Statistical analysis
The statistical analysis was performed using the MINI-
TAB software (MINITAB, State College, PA, Version
13.1, 2002). The data from the experiments were tested
for normality using the Anderson Darling test and for
variance homogeneity prior to any further statistical ana-
lysis. The data were normally distributed with homoge-
neous variances. Thus, the one-way ANOVA statistical
measure was used to determine overall effect of each
treatment. This measure was supplemented by individual
comparison between the different treatments using
Tukey’s method for pairwise comparisons. The results
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ation (SD). Only statistically significant differences, with
P < 0.05, that were found between a treatment group and
the control and between a treatment group and the CCl4
group were considered.
Results
Effects of melatonin and folic acid on CCl4-induced
oxidative stress
The results revealed that CCl4 significantly elevated
both the concentration of hydroperoxide and the
amount of lipid peroxidation. Melatonin, folic acid and
their combination were found to significantly reduce this
high concentration of hydroperoxide, although it was
still significantly higher than that of the control group.
Interestingly, the amount of lipid peroxidation was
restored to the normal baseline concentration observed
in the control group by these three treatments (Table 2).
We showed that glutathione, the most important anti-
oxidant enzyme, was significantly decreased by CCl4
challenge. However, the concentration of glutathione in
animals treated with melatonin, folic acid and their syn-
ergic combination was four to six-fold higher (p < 0.05)
than the concentration of glutathione measured in the
CCl4-treated group. Furthermore, these three treatments
restored the concentration of catalase activity to values
close to that observed in the control group (Table 2).
Effect of melatonin and folic on CCl4-induced TNF-α,
Akt1, Fas and IFN-γ mRNA expression
The expected CCl4-induced hepatocytotoxic effects were
confirmed by the significantly elevated apoptosis recep-
tor Fas and TNF-α mRNA expression levels, but either
melatonin, folic acid or their combination down regu-
lated these expression levels to those observed in the
control group (Table 2). In addition, these three treat-
ments were found to significantly upregulate the expres-
sion of the Akt1 and IFN-γ mRNA compared to the
CCl4 group. This restoration of the Akt1 and IFN-γ
gene expressions in the animals treated with theTable 2 Concentrations of oxidative stress parameters and re
induced in the different groups
Parameters Control group CCL4 M
Blood Hydroperoxide (mg/100 ml) 24 ± 5.0 44.5* ± 6.2 21
Hepatic MDA (nmol/mg protein) 3 ± 0.7 5.6* ± 0.9 2.
Hepatic GSH (μmol/g liver tissue) 12.2 ± 1.8 5* ± 1.8 25
Catalase (Unit/mg protein) 14.4 ± 1.8 7.9* ± 1.0 16
Relative expression of TNF-α mRNA 1.8 ± 0.8 5.6* ± 0.9 1.
Relative expression of Akt1 mRNA 5.7 ± 1.1 1.8* ± 0.5 15
Relative expression of Fas mRNA 0.9 ± 0.3 10.1* ± 0.9 0.
Relative expression of IFN- γ mRNA 18.5 ± 7.2 7.0* ± 2.2 17
The results are expressed as M ± SD. * shows a statistically significant difference (P <combination of melatonin and folic acid was superior to
that observed in the animals treated with only one of
these compounds.
Biochemical analysis and Histopathological examination
Effects of melatonin and folic acid on CCl4-induced liver
enzyme concentrations
The results presented in Table 3 show that CCl4 was
found to significantly elevate the levels of ALP, ALT,
LHD and AST to concentrations that are two-, ten-, two
and a half-, three and a half-, six- and thirty-fold their
normal values, respectively. In addition, the combination
of melatonin and folic acid was found to significantly re-
store the concentrations of both ALP and LDH to their
baseline concentrations. Although the individual treat-
ments with melatonin or folic acid did not normalize the
concentrations of ALT and AST to the values observed
in the control group, they did significantly decrease the
concentrations of these enzymes compared to that
observed in the CCl4-group (Table 3).
Effect of combination of melatonin and folic acid on CCl4
induced lipid profile
The cardiovascular risk indices were significantly ele-
vated as a result of CCl4-induced hepatic injury, and
treatment with melatonin and folic acid restored these
indices. In addition, we found that CCl4 significantly ele-
vated the concentrations of total cholesterol, LDL chol-
esterol and triglycerides. However, melatonin, folic acid
and the combination of these two treatments signifi-
cantly restored the concentration of these parameters to
that measured in the control group. Interestingly, HDL
was found to be significantly reduced by the CCl4 chal-
lenge, a decrease that was not observed when the ani-
mals received any of the three treatments (Table 3).
Effects of melatonin and folic acid on CCl4-induced
concentration of total protein, bilirubin and urea
The results revealed that CCl4 significantly decreased
the concentration of total protein in the serum.lative mRNA expression of TNF-α, AKT1, Fas and IFN-γ
e CCL4+Me Fo CCL4+Fo CCL4+Me + Fo
.5 ± 4.3 32.1* ± 4.2 21.8 ± 3.0 30.6 ± 6.3 27 ± 5.0
1 ± 0.8 4* ± 0.7 2.4 ± 0.7 4.4* ± 0.9 2.1 ± 0.6
.7* ± 7.8 14.7 ± 5.0 28.6* ± 5.8 21.7* ± 5.0 21.2* ± 5.1
.3 ± 1.8 11.5 ± 2.8 16 ± 2.7 10* ± 0.9 14 ± 1.5
6 ± 0.5 3.3* ± 0.7 2.1 ± 0.8 3.2* ± 0.7 1.7 ± 0.5
.2* ± 2.7 5.0 ± 1.3 17* ± 1.8 5.0 ± 1.6 7.0 ± 1.8
8 ± 0.45 8.2* ± 1.2 0.78 ± 0.2 5.5* ± 0.2 2.5* ± 0.7
.5 ± 6.0 8.8* ± 0.9 34.2* ± 4.4 14.6 ± 2.6 20.2 ± 3.0
0.05) in the pairwise comparison between a treatment group and the control.
Table 3 Plasma concentrations of liver enzymes, lipids, total protein, bilirubin and urea from the control and the
different groups
Parameters Control group CCL4 Me CCL4+Me Fo CCL4+Fo CCL4+Me + Fo
ALP (U/L) 232.6 ± 33.5 418.3* ± 67 238.6 ± 62 279.1 ± 34 234.7 ± 43 267.3 ± 61 228 ± 35
ALT (U/L) 27 ± 3.8 369* ± 106 29 ± 3.0 293.5* ± 34 22.7 ± 1.1 205.5* ± 77 156.5* ± 62
AST (U/L) 48.7 ± 4.0 369* ± 91 42.1 ± 4.8 251* ± 48 41 ± 7.2 288.7* ± 112 237.7* ± 71
LDH (U/L) 192.3 ± 63 576* ± 221 165.3 ± 47 317.3 ± 110 178.6 ± 43 363.3 ± 130 337.5 ± 143
Cholesterol (mg/100 ml) 57.7 ± 8.0 87* ± 14 53 ± 6.0 59 ± 9.0 61 ± 5.0 76* ± 14 57 ± 8.6
LDL-C (mg/100 ml) 33 ± 6.6 50* ± 15 37 ± 6.0 38 ± 2.3 36 ± 5.7 44* ± 5.0 36 ± 6.0
HDL (mg/100 ml) 31 ± 5.5 10* ± 4.9 32 ± 5.6 16* ± 7.0 30 ± 5.4 24 ± 7.3 27 ± 6.3
Triglycerides (mg/100 ml) 66 ± 4.3 125* ± 10 51 ± 6.0 82* ± 7.0 65 ± 6.2 70 ± 6.2 66 ± 3.2
Plasma Protein g/100 ml 7.7 ± 0.6 5.5* ± 0.5 7.3 ± 0.9 5.8* ± 0.35 6.7 ± 0.7 5.7* ± 0.7 6.7 ± 0.7
Bilirubin Mg/100 ml 0.246 ± 0.08 0.468 ± 0.17 0.226 ± 0.04 0.324 ± 0.06 0.266 ± 0.06 0.42* ± 0.1 0.355 ± 0.07
Urea Mg/100 ml 40.6 ± 7.3 55.5* ± 10 33.6 ± 5.9 55* ± 9.5 50.8 ± 7.0 48.5 ± 3.0 37.6 ± 5.4
The results are expressed as the M ± SD. * shows a statistically significant difference (P < 0.05) in the pairwise comparison between a treatment group and
the control.
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ally failed to restore the normal concentration of total
protein. However, the synergistic combination of folic
acid and melatonin was uniquely able to restore the con-
centration of total protein to a value that is close to that
measured in the control group. Unlike its effect on the
total protein concentration, the amounts of bilirubin
and urea in the serum of CCl4-challenged rats was two
and one and a half-fold higher than the concentration in
the serum of control rats. We generally observed that
the treatments with melatonin or with the combination
of melatonin and folic acid were better able to restore
the concentrations of these two parameters than treat-
ment with folic acid (Table 3).
Effect of combination of melatonin and folic acid on the
histology of liver
An increased number of mitotic figures, vacuolated
hepatocytes, and eosinophilic hepatocytes characterized
the histological sections of the CCl4-challenged group.
The liver sections obtained from CCl4-challenged rats
that were treated with folic acid showed a large number
of mitotic figures, which were not present in the liver
sections obtained from CCl4-challenged rats that were
treated with melatonin. In addition, the combined treat-
ment of folic acid and melatonin resulted in an improve-
ment in the general hepatic architecture (Figure 1).
Histopathological changes of collagen deposition oc-
curred in CCl4-challenged rats and prevention by the
treatment with melatonin and folic acid are showed in
Figure 2. The tissues of rats treated with CCl4 revealed
extensive accumulation of connective tissue resulting in
formation of continuous interlobular septa, noticeable
alterations and dilations in the central vein and pro-
nounced inflammation as compared to the normalcontrol (Figure 2B, 2C). The group challenged with
CCl4 and treated with melatonin and folic acid resulted
in less destruction of the liver architecture without fibro-
sis and moderate inflammation (Figure 2D).
Discussion
This study investigated the capability of folic acid, mela-
tonin or the combination of these two compounds to
protect against CCl4-induced hepatotoxicity. Our find-
ings confirmed the previous observations that melatonin
[28] and folic acid [29] effectively reduce oxidative stress,
restore the normal concentrations of anti-oxidant
enzymes, and exhibit antihyperlipidemic activity. In
addition, the antioxidant activity of natural products has
a number of beneficial effects in the treatment of various
types of diseases [30].
The hepatotoxicity of CCl4 includes the production of
free radicals and the activation of Kupffer cells and
macrophages, which generate inflammatory and profi-
brogenic mediators. The overproduction of free radicals
is the initial step in a chain of events that eventually
leads to membrane lipid peroxidation and ultimately to
cellular apoptosis and necrosis [31]. The potential
mechanisms of chemical-induced liver apoptosis include
an increase in cytokine concentrations and/or oxidative
stress [32]. In addition, lipid peroxidation, a ROS-
mediated mechanism, has been implicated in the patho-
genesis of various liver injuries and the subsequent liver
fibrogenesis that is observed in experimental animals
[33].
We found that the concentration of MDA and hydro-
peroxide, which are indices of oxidative stress, were ele-
vated in CCl4-challenged rats. However, decreased
concentrations of these two compounds were found in
the liver tissues of those CCl4-rats that were treated
Figure 1 Photomicrographs for liver sections of the different groups A: Photomicrograph of a control liver section showing the normal
histological architecture of hepatic tissues (H&E stain, 400x). B: The histological features of a representative liver section from CCl4-treated
rats (the sections from four rats in this group were investigated), which shows the increased number of mitotic figures (arrow) and the clear
vacuolation of the hepatocytes (H&E stain, 1000x). Insert: In addition to the mitotic figures, eosinophilic hepatocytes (arrow) were detected in
sections from two of the CCl4-treated rats in this group (H&E stain, 400x). C: A representative liver section from CCl4 + Me-treated rats (H&E stain,
400x) was characterized by the absence of the mitotic figures. However, vacuolated hepatocytes and abnormal damaged hepatic tissues were still
found. D: A representative liver section from CCl4 + Fo-treated rats shows many mitotic figures (white arrows), which resemble those detected in
the liver sections from CCl4-treated rats. A number of pyknotic nuclei were detected in the sections from this group (H&E stain, 400x). E: A
representative liver section from CCl4 + Me + Fo-treated rats, which exhibit an improvement of the general hepatic architecture (sections from
five rats in this group were investigated) (H&E stain, 400x). F: A liver section from the group of CCl4 + Me + Fo-treated rats that shows little
improvement (this was observed in the sections from two of the rats) (H&E stain, 400x). G: A representative liver section from Fo-treated rats,
which shows the general hepatic architecture with a small amount of side effects, such as faintly stained nuclei (H&E stain, 400x). H: A
representative liver section from Me-treated rats, which shows the general hepatic architecture with narrow hepatic sinusoids and a large number
of hepatocytes (H&E stain, 400x).
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melatonin and folic acid, which suggests that these com-
pounds can effectively protect against lipid peroxidation.
Melatonin exerts antioxidant protection in different cell
organelles, both in vitro and in vivo [34]. The body has
an effective defense mechanism to prevent and
neutralize damage that is induced by free radicals. These
enzymes constitute a mutually supportive team of
defense against ROS [35]. Melatonin and folic acid were
found to significantly restore the normal concentrations
of GSH and the catalase activity. The catalase enzyme,which exists in all aerobic cells, is a hemeprotein that
metabolizes the decomposition of H2O2 to form oxygen
and water. GSH acts as a non-enzymatic anti-oxidant
that reduces the amount of H2O2, hydroperoxides and
xenobiotic toxicity [36]. The significant decrease of
hydroperoxide in the blood and hepatic tissues con-
firmed that the pre-treatment with folic acid and mela-
tonin could effectively protect against the hepatic lipid
peroxidation that is induced by CCl4. The anti-oxidant
activity and antilipidemic effects of melatonin may en-
hance the modulation of blood pressure and most likely
Figure 2 Histological assessment of liver fibrosis in CCl4-treated rats and the effects of the combination of melatonin and folic acid on
collagen deposition. The extent of matrix deposition (arrow) was measured by Masson’s trichrome staining of liver tissue sections from control
animals (A: 400x), CCl4-treated rats (black arrow: collagen of the very dilated central vein; red arrow: the interlobular collagen deposition) (B:
200x), CCl4-treated rats to show the inflammatory cells (C: 400x) and the rats receiving melatonin and folic acid (black arrow: collagen of the
central vein) (D: 400x).
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damage to the target organ [37]. GSH is a crucial deter-
minant for cell survival or death in oxidative stress con-
ditions [38] and, thus, GSH is critical in reducing the
toxic effects of CCl4. Moreover, the increase in hepatic
GSH concentrations in rats treated with either folic acid,
melatonin or their combination may be due to an in-
crease in the amount of GSH synthesis or regeneration.
ROS upregulates NF-κB, which is required for the in-
duction of pro-inflammatory cytokines, such as IL-1ß,
TNF-α and IL-6 [39]. TNF-α is a key mediator of the
immune and inflammatory responses and controls the
expression of the inflammatory gene network. Therefore,
the overproduction of TNF-α contributes significantly to
the pathological complications observed in many inflam-
matory diseases; for example, pro-inflammatory cyto-
kines can increase the risk of schizophrenia [40].
Similarly, hepatic injury is associated with the upregula-
tion of TNF-α gene expression that was observed in the
CCl4 group; this result is therefore in accordance with
previous studies [41]. Consequently, the overproduction
of TNF-α contributed to the manifestation of the sys-
temic inflammatory response and ultimately to the de-
velopment of organ failure.We found that the upregulation of TNF-α expression
was accompanied by the upregulation of the Fas genes
in CCl4-induced liver injury. The Fas protein is a type I
membrane receptor that belongs to the TNF-receptor
superfamily. Mita et al. [42] found that the expression of
FasL by macrophages plays a role in their pathogenesis.
In the present study, Fas mRNA expression was sig-
nificantly upregulated in CCl4- injected rats. Similarly,
Zhang et al. [43] found that the expression of Fas is
increased in CCl4-induced liver fibrosis. Activation of
the Fas receptor by the FasL induces apoptosis via the
activation of the caspase cascade [44]. Therefore, the
upregulation of both TNF-α and Fas clearly explains the
hepatic tissue damage and dysfunction that was
observed in the CCl4 group. Furthermore, hepatic injury
in rats leads to elevations of serum AST and ALT and an
increased incidence and severity of histopathological
hepatic lesions. The present study revealed a significant
increase in the concentrations of AST, ALT and ALP
upon exposure to CCl4, which indicates considerable
hepatocellular injury. In addition, an increase in serum
AST and ALT concentrations by CCl4 has been attribu-
ted to hepatic structural damage because these entities
are normally localized to the cytoplasm and are only
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The oxidative stability that is induced by the combin-
ation of melatonin and folic acid may mediate a downre-
gulation of NF-κB activation, which results in the
suppression of the inflammatory cascade and the low
concentrations of TNF-α that were observed. Thus, the
hepatic injury markers were significantly retarded in the
animals that received any of these treatments. In fact,
folic acid and melatonin significantly attenuated the
increased concentrations of the serum liver enzymes that
were induced by CCl4 and therefore led to the subse-
quent restoration of these to normal concentrations.
The effect of folic acid and melatonin was further con-
firmed through histopathological examinations. It was
found that pre-treatment with the combination of mela-
tonin and folic acid had broad anti-inflammatory effects
and attenuated the allergic inflammation in the CCl4-
challenged rats. This amelioration of the hepatic tissues
by melatonin and folic acid seemed to be mediated by
the inhibition of oxidative stress and therefore the sup-
pression of NF-κB, the key regulator of inflammatory
production, which results in the decreased production of
pro-inflammatory cytokines.
The Akt1 signal is critical for cell survival that is
triggered by growth factors, the extracellular matrix, and
other stimuli [46]. Therefore, there is impaired Akt and
eNOS activation in cirrhotic livers [47]. We found
a downregulation of Akt1 gene expression in CCl4-
challenged rats. The concentration of Akt1 mRNA expres-
sion was markedly restored in CCl4-rats that were pre-
treated with the combination of melatonin and folic acid.
Previous studies have shown that Myr-Akt gene therapy
can restore Akt activation and NO production in cirrhotic
livers, which suggests that this therapy may be helpful in
treating portal hypertension [47]. The restorative capacity
of melatonin and folic acid was also confirmed in the
complete restoration of the IFN- γ mRNA expression to
normal concentrations. The proteins EMSY and BRAC2
repress a number of IFN-stimulated genes; however, an
Akt1-dependent pathway contributes to the full activation
of IFN-stimulated genes by relieving this repression [48].
Similar data establishes that Akt activity is essential for the
upregulation of key IFN-α- and IFN-γ-inducible proteins,
which have important functional consequences in the in-
duction of IFN responses [49]. In addition, the retrovirus-
mediated expression of activated Akt in primary T cells
from CD28-deficient mice is capable of selectively restor-
ing the production of IL-2 and IFN-γ [50]. We proved that
the activation and upregulation of Akt1 was accompanied
by an improvement in the biomarkers of hepatic damage,
the histological architecture and liver function.
We confirmed the hypolipidemic effect of melatonin
and folic acid in CCl4-treated rats, which was manifestedby the low concentrations of cholesterol, triglycerides,
and LDL and the increased HDL concentrations. Similar
findings were also reported for other experimental mod-
els, which observed a decline in LDL and total choles-
terol and an increase in HDL concentrations in animals
treated with melatonin [51]. This effect may be related to
the enhancement of the catabolism of cholesterol to form
bile acids [51] and the inhibition of cholesterol synthesis
and LDL receptor activity [52].
HDL plays an essential role in the transport of choles-
terol to the liver for excretion into bile acids [53], which
are cytoprotective in hepatocytes because of their ability
to activate phosphatidylinositol-3-kinase and its down-
stream signal Akt [54]. We confirmed the upregulation
of the Akt1 signal by the combination of melatonin and
folic acid. The combination treatment was better able to
restore the elevated concentrations of cholesterol, trigly-
cerides and inflammatory indicators than the individual
treatments. A significant increase in the arterial elasticity
index, a significant improvement in glucose and lipid
metabolism, and a significant increase in HDL choles-
terol have also been observed in patients treated with
anti-oxidants [55]. Additionally, the beneficial effect of
anti-oxidants on LDL oxidation has been previously
demonstrated [56].
Our findings provide evidence of the potential anti-
oxidant and anti-inflammatory effects of melatonin and
folic acid. This combination restored normal oxidative
stress concentrations, which might inhibit NF-κB and
thus downregulate TNF-α and Fas mRNA expression. In
addition, melatonin and folic acid markedly upregulated
the cell survival signal, Akt1, and the IFN-γ concentra-
tions. Furthermore, the restoration of the survival signal-
ing genes that was induced by melatonin and folic acid
also resulted in significant improvements to the liver
function and the histological architecture. There are cur-
rently no data on the treatment of CCl4-induced hepatic
injury with melatonin and folic acid that would indicate
whether this intervention has a significant clinical im-
pact. We have elucidated a potential role for these sub-
stances in the treatment of hepatic injury that needs to
be intensively investigated in future research that focuses
on patient oriented outcomes.
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